Result of AGM
05 9월 2009 - 1:44AM
UK Regulatory
TIDMNWBS TIDMNWBT
RNS Number : 5959Y
Northwest Biotherapeutics Inc
04 September 2009
+-----------------------------------------+-----------------------------------------+
| For immediate release | 4 September 2009 |
+-----------------------------------------+-----------------------------------------+
Northwest Biotherapeutics, Inc.
("NWBT", "Northwest" or the "Company")
NORTHWEST BIOTHERAPEUTICS HOLDS ANNUAL GENERAL MEETING
BETHESDA, MD -September 4, 2009 - Northwest Biotherapeutics, Inc. (AIM: NWBT and
NWBS; OTCBB: NWBO) today announces that all resolutions put to the Company's
shareholders at today's Annual General Meeting held today in Bethesda, MD, USA
have been approved. The resolutions included: (1) the approval of Linda F.
Powers as a Class Two Director; (2) the increase in the number of authorized
shares in the Company from 100,000,000 to 150,000,000; and (3) the cancellation
of the Company's listing on the London Stock Exchange's AIM market ("AIM"). The
Company plans to continue its listing in the U.S., on the NASD Over the Counter
Bulletin Board Market ("U.S. listing") and plans to file an S1 registration
statement under which the Company's shares held on AIM may become tradable on
the US market. The trading of the Company's shares on AIM is expected to be
cancelled on September 14, 2009.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing
immunotherapy products that treat cancers more effectively than current
treatments, without toxicity, on a cost-effective basis. The Company has two
broad platform technologies: dendritic cell-based vaccines and therapeutic
antibodies. The Company is in a large Phase II clinical trial in GBM, with 13
clinical sites across the U.S. The Company has also received clearance from the
FDA for a large Phase III trial in prostate cancer, and for Phase I trials in
five other cancers. The Company has started, and is currently enrolling patients
in, a Phase I/II trial with DCVax for recurrent metastatic ovarian cancer. The
Company's second technology platform, involving antibodies to CXCR4, is at the
late pre-clinical development stage.
For further information about clinical sites and Company information please
visit the company web site at www.nwbio.com.
Disclaimer
Statements made in this news release that are not historical facts, including
statements concerning future securities registrations or other filings with the
U.S. Securities and Exchange Commission ("SEC"), future treatment of patients
with GBM using DCVax -Brain, and other future clinical trials, are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as "may," "expects," "believes,"
"intends," "anticipates," and similar expressions are intended to identify
forward-looking statements. Actual results may differ materially from those
projected in any forward-looking statement. Specifically, there are a number of
important factors that could cause actual results to differ materially from
those anticipated, such as the SEC's review and evaluation of securities
registrations or other filings, the Company's ability to raise additional
capital, risks related to the Company's ability to enroll patients in its
clinical trials and complete the trials on a timely basis, uncertainties related
to the clinical trials process, uncertainties about the timely performance of
third parties, and uncertainties about whether the Company's products will
demonstrate safety and efficacy. Additional information on these and other
factors, which could affect the Company's results, is included in its SEC
filings and the Risk Factors section of the Form S-1 that the Company is
preparing to file. Finally, there may be other factors not mentioned above or
included in the Company's SEC filings or upcoming Form S-1 that may cause actual
results to differ materially from those projected in any forward-looking
statement. You should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update any forward-looking
statements as a result of new information, future events or developments, except
as required by securities laws.
For further information, please contact:
+----------------------------------------------------------------+----------------------+
| Northwest Biotherapeutics, Inc. | +1 240 497 9024 |
+----------------------------------------------------------------+----------------------+
| Alton L. Boynton, Chief Executive Officer | |
+----------------------------------------------------------------+----------------------+
| | |
+----------------------------------------------------------------+----------------------+
| Buchanan Communications | +44 (0)20 7466 5000 |
+----------------------------------------------------------------+----------------------+
| Lisa Baderoon (lisab@buchanan.uk.com) / Mary-Jane Johnson / | |
| Catherine Breen | |
+----------------------------------------------------------------+----------------------+
| | |
+----------------------------------------------------------------+----------------------+
| Collins Stewart Europe Limited | +44 (0)20 7523 8350 |
+----------------------------------------------------------------+----------------------+
| Adrian Hadden/ Adam Cowen | |
+----------------------------------------------------------------+----------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGDGGGLVDFGLZM
Northw.Bio Regs (LSE:NWBS)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Northw.Bio Regs (LSE:NWBS)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
